Physician profile
Mikhail Korogluyev
NPI 1083820252
$24,386.88
in general payments reported to CMS, 2019-2025
55 companies · $3,136 in 2025
The $3,136 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,654 · 2020: $3,840 · 2021: $4,830 · 2022: $3,961 · 2023: $3,171 · 2024: $2,795 · 2025: $3,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,102.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,401.17 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $2,349.80 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,975.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,929.85 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Scilex Pharmaceuticals INC. | $1,535.93 | 2019-2025 | Ztlido |
| Pfizer INC. | $1,451.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,162.63 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $1,151.24 | 2019-2023 | |
| Allergan, INC. | $1,132.34 | 2019-2022 | |
| Amgen INC. | $1,094.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,001.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $990.71 | 2019-2022 | |
| Novo Nordisk INC | $635.38 | 2019-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $596.88 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $480.54 | 2021-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Korogluyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.